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Objective: The subjective experience of psychotic patients toward treatment is a key factor in 
medication adherence, quality of life, and clinical outcome. The aim of this study was to assess 
the subjective well-being in patients with schizophrenia and to examine its relationship with 
the presence and severity of depressive symptoms.
Methods: A multicenter, cross-sectional study was conducted with clinically stable outpatients 
diagnosed with schizophrenia. The Subjective Well-Being under Neuroleptic Scale – short ver-
sion (SWN-K) and the Calgary Depression Scale for Schizophrenia (CDSS) were used to gather 
information on well-being and the presence and severity of depressive symptoms, respectively. 
Spearman’s rank correlation was used to assess the associations between the SWN-K total score, 
its five subscales, and the CDSS total score. Discriminative validity was evaluated against that 
criterion by analysing the area under the curve (AUC).
Results: Ninety-seven patients were included in the study. Mean age was 35 years (standard 
deviation = 10) and 72% were male. Both the total SWN-K scale and its five subscales correlated 
inversely and significantly with the CDSS total score (P , 0.0001). The highest correlation was 
observed for the total SWN-K (Spearman’s rank order correlation [rho] = −0.59), being the other 
correlations: mental functioning (−0.47), social integration (−0.46), emotional regulation (−0.51), 
physical functioning (−0.48), and self-control (−0.41). A total of 33 patients (34%) were classified 
as depressed. Total SWN-K showed the highest AUC when discriminating between depressive 
severity levels (0.84), followed by emotional regulation (0.80), social integration (0.78), physical 
functioning and self-control (0.77), and mental functioning (0.73). Total SWN-K and its five 
subscales showed a significant linear trend against CDSS severity levels (P , 0.001).
Conclusion: The presence of moderate to severe depressive symptoms was relatively high, and 
correlated inversely with patients’ subjective well-being. Routine assessment of patient-reported 
measures in patients with schizophrenia might reduce potential discrepancy between patient and 
physician assessment, increase therapeutic alliance, and improve outcome.
Keywords: schizophrenia, subjective well-being, patient-reported outcome, depressive 
symptoms
Introduction
Schizophrenia is a severe mental disease with devastating effects on the lives of 
patients and their caregivers.1
The systematic assessment of patient perspective may provide valuable information 
that could be missed when only clinical evaluation is relied on. In chronic conditions 
such as schizophrenia, there are advantages to using patient-reported measures to 
understand complex needs and improve alliances between patients and clinicians.2
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Although since the 1960s there has been some interest 
in the subjective experience of patients with psychoses, until 
recently it has received little attention as a patient-reported 
outcome.3,4 In the last two decades, several psychometric 
initiatives have lead to the validation of several scales on 
subjective experience with antipsychotic drugs, including 
the Dysphoric Response Index, the Neuroleptic Dysphoria 
Scale, the Drug Attitude Inventory, the Rating of Medication 
  Influences, the Subjective Well-Being under Neuroleptic Scale 
(SWN), the Attitudes Towards Neuroleptic   Treatment, the 
Medication Adherence Rating Scale, and the Personal Evalu-
ation of   Transition in Treatment Scale.5–12 These scales differ 
not only in their application framework and administration 
form, but also in the type of questions framed to the problem of 
subjective experience.13 The SWN scale is a patient-reported 
outcome designed to assess patients’ subjective experiences 
regardless of their mental state and medication stabilization. 
Contrary to scales that focus exclusively on medication-
related outcome, the SWN also assesses subjective perception 
in other dimensions of quality of life.3
Depressive symptoms are common in patients with 
schizophrenia, ranging up to 65%.14,15 Their presence 
has been associated with worse clinical outcome, work 
  impairment, a poorer quality of life, and higher rates of 
relapse and suicide.16
The aim of this study was to assess the subjective well-
being in a sample of stable outpatients with schizophrenia and 
to determine its relationship with the presence and severity 
of depressive symptoms.
Methods
A non-interventional, cross-sectional study was conducted 
in 20 mental health centers throughout Spain. The study was 
approved by the institutional review board of the Fundació 
Sant Joan de Deu (Barcelona, Spain) (Clinical Trial Registry 
#NCT00749970). Written informed consent was obtained 
from all patients. The criteria for patient recruitment were: 
18–65 years of age; a diagnosis of schizophrenia, schizoaf-
fective disorder, or schizophreniform disorder according to 
the Diagnostic and Statistical Manual of Mental Disorders: 
Fourth Edition; Text Revision;17 follow-up as an outpatient; 
clinically stable as judged by the investigators, considering 
stable those patients in whom a change in disease severity was 
not expected within 1 month after recruitment and who have 
not had any significant changes in antipsychotic medication 
for at least 3 months prior to the enrollment.
The Subjective Well-being under Neuroleptic – short ver-
sion (SWN-K) is a self-rated scale consisting of 20   questions 
concerning physical and mental function, self-control, 
emotional regulation, and social integration. The total score 
ranges from 20 to 120 points, with higher scores indicating 
greater well-being. This scale has been reported with good 
psychometric qualities for its potential utility in both clinical 
practice and clinical trials with schizophrenic patients treated 
with antipsychotic drugs.3,18
The Calgary Depression Scale for Schizophrenia (CDSS) 
is a physician-rated measure specifically designed to assess 
depression in patients with schizophrenia.19 It is a nine-item 
questionnaire with a global score range from 0 to 27 points. It 
has been validated in independent studies and recommended 
as the gold standard for assessing depression in schizophrenia 
for clinical trials.20
Demographic and clinical characteristics were described 
using mean, standard deviation, and 95% confidence interval 
(CI) for continuous measures. Spearman’s rank correlation 
was used to assess associations between SWN-K total score, 
its five subscales, and CDSS total score. Following previous 
results from the Spanish version of the CDSS, a 4/5 cut-off 
point was chosen to dichotomize the clinical sample between 
mild and moderate to severe depressive symptoms.21 The 
discriminative validity of the SWN-K and its subscales was 
evaluated against that criterion by analyzing the area under 
the receiver operating characteristics curve (AUC). Finally, 
to evaluate a dose–effect linear trend, an ordinal three-group 
depression severity was created by using cut-off points at 
3/4 and 6/7 for the CDSS total score. The appropriateness, 
or not, of a dose–effect linear trend was then evaluated by 
comparing nested models with a likelihood ratio test: the 
model including the CDSS information coded as a three-level 
factor and the model with the CDSS included as a variate.
Results
A total of 97 patients were included in the statistical analysis. 
The mean age was 35 years (standard deviation [SD] = 10), 
with males comprising 72% of the sample. Most patients had 
a diagnosis of schizophrenia (n = 77), followed by schizo-
affective disorder (n = 18), and schizophreniform disorder 
(n = 2). Mean SWN-K total score was 83.5 (SD = 14.0). 
Demographic and clinical characteristics of the sample are 
shown in Table 1.
Thirty-three patients (34%, 95% CI = 24%–44%) were 
classified as depressed using the 4/5 points CDSS cut-off 
criterion.
Both the SWN-K total score and its five subscales cor-
related inversely and significantly with the CDSS total score 
(P , 0.0001). The highest correlation was observed for the 
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total SWN-K (rho = −0.59); the other correlations with the 
CDSS were as follows: mental functioning (−0.47), social 
integration (−0.46), emotional regulation (−0.51), physical 
functioning (−0.48), and self-control (−0.41) (Table 2).
SWN-K total score showed the highest AUC when 
discriminating among depressive severity levels (0.84), 
followed by emotional regulation (0.80), social integration 
(0.78), physical functioning, self-control (0.77), and mental 
functioning (0.73). Both the total SWN-K and its five sub-
scales showed a significant linear trend against CDSS severity 
levels (P , 0.001) (Table 3).
Discussion
Although patients with schizophrenia may traditionally have 
been treated as passive recipients of treatment, in the last few 
decades they have increasingly been seen as active partners in 
care whose views and opinions matter.2 New constructs and 
measures are shifting the emphasis from symptom manage-
ment to maximizing the patient’s quality of life and functional 
recovery.22 In fact, the US Food and Drug Administration 
has issued guidance for the use of patient assessments as 
effectiveness endpoints in clinical trials.23
The subjective experience of psychotic patients toward 
treatment is a key factor in medication adherence, quality of 
life, and clinical outcome.3 Both the SWN9 and its 20-item 
short version3 were developed to assess the subjective well-
being of patients treated with antipsychotic drugs without 
focusing differently on adverse effects of treatment or 
symptoms severity.3,9 As a consequence, the SWN contents 
should overlap those assessed by independent clinician-rated 
outcomes regarding adverse effects and symptoms severity, 
as well as contents covered by other patient-reported mea-
sures concerning attitudes to medication. However, a recent 
publication does point to the practical independence of the 
SWN-K from the Drug Attitude Inventory, suggesting that 
attitudes to medication and well-being might represent non-
overlapping dimensions.18
Depression is a common symptom over the course of 
schizophrenia.14 Patients with depressive symptoms suf-
fer significantly more negative symptoms at discharge, 
have impaired subjective well-being and functioning, 
and a higher risk of suicide.16,24 The high prevalence of 
depressive symptoms in schizophrenia and, in particular, 
its negative impact on prognosis make detection and treat-
ment essential.
A limitation of this study was the lack of assessment 
of additional factors related to quality of life and patient 
well-being, such as comorbidity, substance abuse, type of 
antipsychotic treatment, or medication adherence.
The presence of moderate to severe depressive symptoms 
in the sample of clinically stable outpatients in this study was 
relatively high (34%) and also correlated inversely with their 
subjective well-being. This highlights the relevance of recog-
nizing depressive symptoms in patients with schizophrenia 
and the need for close monitoring.
Involving patients with schizophrenia in their own 
treatment is feasible, except perhaps in a few cases where 
Table 1 Patient demographics and clinical characteristics
N = 97
Age (years) mean (SD) 35.0 (10.0)
Gender (male) (%) 72.0
Living status (alone) (%) 11.5
Marital status (single) (%) 92.8
Age at onset (years), mean (SD) 22.0 (8.0)
Number of hospitalizations (median) (SD) 3.0 (3.7)
CGI-S score (mean) (SD)  3.6 (1.3)
PANSS total score (mean) (SD) 65.0 (21.4)
SWN-K total score (mean) (SD) 83.5 (14.0)
Abbreviations: CGI-S, Clinical Global Impression – Severity Scale; PANSS, Positive 
and Negative Syndrome Scale; SWN-K, Subjective Well-Being under Neuroleptic 
scale – short version.
Table  2  Spearman  correlations  and  area  under  the  curve 
between SWN-K and CDSS
SWN-K CDSS total score 
rho (95% CI)*
CDSS 4/5 cut-off 
AUC (95% CI)
Total score −0.59 (−0.71 to −0.44) 0.84 (0.75 to 0.92)
Mental functioning −0.47 (−0.61 to −0.30) 0.73 (0.61 to 0.84)
Social integration −0.46 (−0.60 to −0.29) 0.78 (0.68 to 0.88)
Emotional regulation −0.51 (−0.64 to −0.34) 0.80 (0.70 to 0.89)
Physical functioning −0.48 (−0.62 to −0.31) 0.77 (0.67 to 0.87)
Self-control −0.41 (−0.56 to −0.22) 0.77 (0.68 to 0.87)
Note: *All P-values ,0.0001. 
Abbreviations: SWN-K, Subjective Well-being under Neuroleptic Scale – short 
version; CDSS, Calgary Depression Scale for Schizophrenia; AUC, area under the 
curve; CI, confidence interval.
Table  3  Discriminative  performance  of  the  SWN-K  against 
CDSS depression levels
SWN-K CDSS # 3 
Mean (SD)
4 $ CDSS # 6 
Mean (SD)
CDSS $ 7 
Mean (SD)
Total score 89.8 (10.6) 81.1 (10.0) 66.9 (12.7)
Mental functioning 17.0 (3.0) 15.8 (3.4) 11.7 (4.2)
Social integration 17.8 (3.3) 16.3 (3.3) 13.2 (2.9)
Emotional regulation 18.9 (2.9) 15.8 (2.7) 14.0 (4.3)
Physical functioning 18.6 (3.1) 17.0 (3.3) 13.8 (3.3)
Self-control 17.6 (2.9) 16.7 (2.5) 13.6 (2.7)
Note: All P-values for linear trend ,0.001. 
Abbreviations: SWN-K, Subjective Well-being under Neuroleptic scale – short 
version; CDSS, Calgary Depression Scale for Schizophrenia; SD, standard deviation.
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individuals have severe cognitive dysfunction or extremely 
reduced insight.25
Therefore, systematic routine assessment, using both 
clinician-rated and patient-reported measures, might help to 
gather more in-depth clinical information and increase the 
patient’s confidence.
Disclosure
This study was sponsored by AstraZeneca Spain. JM and TD 
are employees of AstraZeneca.
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